Call Us for Support
+91 9654860915
Google Reviews
4.8
Call Us for Support
+91 9654860915
Sourced directly from the authorized manufacturer network to ensure authenticity and quality.
Ready to proceed? Start a request for Vorolanib on our secure patient portal to submit your prescription, upload documents and track your approval status.
Supplied with complete CDSCO-approved import and customs documentation, including Form 12A & 12B, CDEC, GST Bill of Entry, Commercial Invoice, and Packing List.
Manufacturer / Innovator:
China
Regulatory Approval:
Your Trustworthy Partner For Named Patient Program
Over a decade of trusted expertise in Named Patient Access to innovative and life-saving medicines.
100% CDSCO-compliant processes ensuring safe, ethical, and responsible medicine access.
Medicines sourced from authorized manufacturers with full batch traceability.
EU-GDP compliant warehousing for secure, quality-controlled global distribution.
Temperature-controlled logistics ensuring safe, reliable, and timely medicine delivery.
Vorolanib is a once-daily tablet for advanced kidney cancer that has grown despite earlier targeted treatment. It is made by Betta Pharmaceuticals in Hangzhou, China, and sold there as 伏美纳® (Fumeina). Its Chinese name is 伏罗尼布片, and in research it was called CM082. It is always taken together with another tablet, everolimus.
China's National Medical Products Administration (NMPA) approved it in June 2023 as a Category 1 innovative drug, for:
It is a prescription cancer medicine and should only be used under a medical oncologist or uro-oncologist. Betta reports that it was added to China's national reimbursement drug list in December 2023.
Kidney cancers depend heavily on new blood vessels to feed their growth. Vorolanib is a multi-target kinase inhibitor that blocks VEGFR2, PDGFR, KIT, FLT3 and RET, switches that drive blood-vessel growth and tumour growth. Everolimus blocks a different pathway, called mTOR, inside the cancer cell. Using the two together attacks the tumour from two sides.
The phase 3 CONCEPT trial, published in the European Journal of Cancer in 2023, enrolled 399 people in China whose kidney cancer had grown after one earlier VEGFR-targeted tablet. They were split into three equal groups: vorolanib plus everolimus, vorolanib alone, or everolimus alone.
Survival data were not mature at the time of publication.
In the CONCEPT trial registration, vorolanib was taken as:
Each box holds 20 tablets of 100 mg, which is 10 days of treatment at 200 mg a day, so about three boxes cover one 28-day cycle. Your oncologist sets the exact plan and may lower the dose if side effects occur.
This information is not a treatment plan. For personalized medical advice, consult your doctor and refer to the full prescribing information.
Overall safety: almost everyone in the CONCEPT trial had some side effect. Severe (grade 3 or higher) treatment-related side effects occurred in 72.2% of patients on the combination, compared with 53.4% on everolimus alone and 39.1% on vorolanib alone. This means the combination needs regular check-ups and blood and urine tests.
The detailed side-effect list comes from the earlier phase 1 study of vorolanib plus everolimus in 22 patients (EBioMedicine, 2020). Most effects were mild to moderate:
Everolimus has its own warnings and side effects, which your oncologist will explain before you start. Safety in pregnancy, breastfeeding and children has not been established.
Step 1 – Search & request your medicine: The patient or treating doctor submits a request with basic details to initiate the access process.
Step 2 – Verification & eligibility review: The team verifies availability and reviews eligibility against regulatory and clinical requirements to ensure a compliant pathway.
Step 3 – Receive quote & delivery timeline: A transparent quotation is shared, covering medicine cost, logistics, and a clear delivery timeline.
Step 4 – Regulatory approval process: Assistance is provided to secure the approvals and documentation required for legal cross-border access.
Step 5 – Temperature-controlled import & handling: The medicine is sourced and transported under strict GDP-compliant conditions to maintain product integrity.
Step 6 – Secure delivery: The medicine is delivered to the patient or treating hospital, with updates provided at each stage.
Note: From request to delivery, every step is designed to ensure your treatment reaches you safely, compliantly, and without unnecessary delays.
The tablets can be imported only in the patient's name, by the patient or a government hospital, in line with India's import regulations for unapproved medicines. You will need:
Once we have received and checked a valid prescription and, where needed, an import permit.
No. It is approved only in China. It has no CDSCO approval, it is not sold in Indian pharmacies, and the US FDA and European Medicines Agency have not approved it either.
Patients can still get it legally through the Named Patient Program (NPP), which allows a medicine not registered in India to be imported for one specific patient on a prescription. For another kidney cancer medicine we help patients import, see our page on Welireg.
It can be made available to patients, doctors, and hospitals across major cities in India, including Gurgaon, Delhi, Bangalore, Mumbai, Navi Mumbai, Thane, Hyderabad, Mysore, Kerala, Chennai, Coimbatore, Madurai, Kolkata, Ahmedabad, Surat, Vadodara, Pune, Nagpur, Nashik, Jaipur, Udaipur, Lucknow, Kanpur, Gorakhpur, Chandigarh, Mohali, Faridabad, Noida, Ghaziabad, Kochi, Trivandrum, Kozhikode, Thrissur, Kannur, Mangalore, Bhubaneswar, Patna, Ranchi, Raipur, Guwahati, Visakhapatnam, Vijayawada, Goa, Jammu, Srinagar, Dehradun, Bhopal, Indore, Ludhiana, Amritsar, and others — and can facilitate delivery to the patient's treating hospital. Orders are confirmed only after receipt of a valid doctor's prescription and an import permit, where applicable.
NamedPatientProgram.com (NPP) sources this medicine through the manufacturer's authorised supply channels in China and arranges supply to patients, doctors, and hospitals under applicable legal provisions. Each box holds 20 tablets of 100 mg, so about three boxes cover a 28-day cycle at the trial dose. The tablets travel in their sealed original packs under temperature-controlled shipping, stored as directed on the pack. All prescriptions are dispensed and checked by registered pharmacists and dispatched from New Delhi, India, after legal requirements are fulfilled.
For the current cost in India and availability, contact NPP via WhatsApp at +91 98104 69557 | Toll-Free: 1800-1200-365 or email info@namedpatientprogram.com.
Patients across India can access this medicine through regulated import pathways, with delivery arranged to the patient or the treating hospital on a valid specialist's prescription.
Uro-oncology departments in Delhi treat kidney cancer patients from across North India, and our New Delhi dispatch point means short delivery times.
Tablets can be delivered to the patient's home or the treating hospital, cycle by cycle.
Oncologists in Bangalore can request the medicine for a named patient and receive a written quote first.
A long-standing referral hub for kidney cancer surgery and treatment in South India.
We plan supply a cycle ahead so the daily tablets never run out.
Patients in Kolkata and the eastern states can use the same documented import route.
Families in Pune receive updates from prescription check to delivery.
The treating oncologist can send us the prescription and treatment history to begin.
Patients treated at hospitals in Vellore can have tablets sent directly to them or the hospital.
Serves patients from Punjab, Haryana and Himachal Pradesh, with delivery to the patient or the treating hospital.
We arrange delivery across Uttar Pradesh for patients on long-term oral treatment.
Patients across Kerala can receive their supply in Kochi and nearby cities.
Access can also be coordinated for patients in other Indian cities, subject to a valid prescription and regulatory requirements.
Written By
Nitin GoswamiDeputy Manager – Content & Social Media, Ikris Pharma Network
Sources: NMPA • CDSCO
Last Updated: 19 October 2026
Our specialists are here to guide you through every step of the medicine access process.
Mail Us At:
info@namedpatientprogram.comContact Us:
+91 9654860915Send us a message
